Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BVS
BVS logo

BVS News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

BVS News

Conexeu Sciences Inc. Begins Trading on Nasdaq

May 22 2026PRnewswire

Conexeu Sciences Inc. Successfully Debuts on Nasdaq

May 22 2026Newsfilter

Bioventus (BVS) Q1 2026 Earnings Transcript

May 06 2026NASDAQ.COM

Bioventus Q1 2026 Earnings Call Highlights

May 06 2026seekingalpha

Bioventus Q1 Earnings Exceed Expectations

May 06 2026seekingalpha

Bioventus Reports 7% Revenue Growth in Q1

May 06 2026Newsfilter

TELA Bio Announces Board Refreshment Plan for Growth

Apr 30 2026Globenewswire

Bioventus Q4 2025 Earnings Call Highlights

Mar 05 2026seekingalpha

BVS Events

06/30 14:00
AWS Invests $1 Billion to Establish Forward Deployed Engineering Organization
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly.NEW UNIT:Francessca Vasquez, Vice President of Frontier AI Engineering and Services, AWS, said in a blog post, "I'm excited to announce that we are meeting that demand by creating a dedicated AWS Forward Deployed Engineering organization. Backed by a $1B investment, the AWS FDE model is different in three key ways: it is agentic-first, it compresses timelines from months to days, and it is designed so customers are self-sufficient when a deployment ends. AWS FDE embeds AWS frontier teams-working with purpose-built agents-directly inside customer teams. These experienced engineers, many of whom build our AWS AI services, partner with a customer's business, engineering, and security teams to build and deploy production AI systems with their data, governance, and processes. Unlike traditional consulting that assesses, recommends, and treats each deployment as a standalone project, AWS FDE builds for the long term. Customers leave AWS FDE deployments with both new solutions and new engineering capabilities. Along with agentic systems running in their own AWS environment, they gain lasting AI skills, workflows, and patterns they can use to innovate independently. Deployments are structured around shared goals and business results, not billable hours. When customers succeed, we succeed."CLAUDE SCIENCE:Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a broader push to become a major platform in biology and life sciences backed by rapidly growing scale and financial resources comparable to leading drug companies, STAT's Matthew Herper and Brittany Trang. Publicly traded companies in the pharmaceutical space include AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Rocheand Sanofi.CLAUDE APPS GETAWAY:Anthropic introduced the Claude apps gateway for Amazon Bedrock and Google Cloud. Previously, running Claude Code on these platforms has meant provisioning a cloud credential per developer, manually pushing settings to every laptop, and standing up separate tooling to see per-developer spend. The gateway is a self-hosted control plane that gives you corporate SSO login, centrally enforced policy, role-based access, and per-user cost attribution for Claude Code. The gateway is run as a single stateless container deployed on Linux and backed by a PostgreSQL database. It holds your upstream credential, authenticates developers against your identity provider, distributes and enforces managed settings, and reports per-user usage to a collector you operate. Onboarding a developer means adding them to your Identity Provider. Offboarding means removing them.Meanwhile, Anthropic said that, starting Monday, Claude models are generally available in MicrosoftFoundry, hosted on Azure. "Claude runs in your Azure environment with the authentication, billing, and governance controls your teams already use," Anthropic said. "You can choose where inference is processed, including a US data zone for teams with data residency requirements. Anthropic operates the inference and is the data processor."
05/06 08:10
Bioventus Raises FY26 Revenue Guidance to $600M
Consensus 75c. Backs FY26 revenue view $600M-$610M, consensus $604.86M. Raises FY26 cash from operations view to $84M-$89M from $82M-$87M. The company said, "Based on accelerated cash flow and faster than anticipated debt repayment, Bioventus is raising its full-year 2026 financial guidance for Adjusted EPS and Cash from Operations."
05/06 08:10
Bioventus Q1 Revenue $132.09M, Exceeds Expectations
Reports Q1 revenue $132.09M, consensus $129.9M. "Our team delivered a strong start to 2026, driven by continued momentum in our core businesses and disciplined execution across our commercial and operational priorities," said Rob Claypoole, Bioventus President and Chief Executive Officer. "We are focused on delivering above market growth for the year, while maintaining peer-leading gross margins, which allows us to reinvest in our multiple growth drivers, expand profitability, and generate strong cash flow, positioning Bioventus to deliver sustainable long-term shareholder value."

BVS Monitor News

No data

No data

BVS Earnings Analysis

No Data

No Data

People Also Watch